CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy

Clinical and Experimental Immunology

Volumn 175, Issue 2, 2014, Pages 181-191

  Abraham, P M ^a   Quan, S H ^a   Dukala, D ^a   Soliven, B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Autoimmunity; B cells; CIDP; Co stimulatory molecules; Guillain Barr syndrome

Indexed keywords

CD19 ANTIBODY; CD19 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYNEUROPATHY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MOUSE; NONHUMAN; PLASMABLAST; POLYNEUROPATHY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN;

AUTOIMMUNITY; B CELLS; CIDP; CO-STIMULATORY MOLECULES; GUILLAIN-BARRÉ SYNDROME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD19; B-LYMPHOCYTES; CELL PROLIFERATION; DOWN-REGULATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MYELIN P0 PROTEIN; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PLASMA CELLS; POLYNEUROPATHIES; TH1 CELLS;

EID: 84891602115     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12215     Document Type: Article

References (53)

1. Salomon B, Rhee L, Bour-Jordan H etal. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 2001; 194:677-684.
2. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201:723-735.
3. Yoshida T, Jiang F, Honjo T, Okazaki T. PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. Proc Natl Acad Sci USA 2008; 105:3533-3538.
4. Horste GM, El-Haddad H, Mausberg AK, Martin S, Hartung HP, Kieseier B. Spontaneous demyelinating autoimmune neuropathy in ICAM-1 deficient NOD mice [Abstract]. Neurology 2010; 74:A490.
5. Kim HJ, Jung CG, Dukala D etal. Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy. J Neuroimmunol 2009; 214:93-100.
6. Ubogu EE, Yosef N, Xia RH, Sheikh KA. Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model. J Peripher Nerv Syst 2012; 17:53-61.
7. Bour-Jordan H, Thompson HL, Bluestone JA. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol 2005; 175:5649-5655.
8. Kim HJ, Jung CG, Jensen MA, Dukala D, Soliven B. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J Immunol 2008; 181:8753-8760.
9. Louvet C, Kabre BG, Davini DW etal. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med 2009; 206:507-514.
10. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000; 47:765-775.
11. Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:286-292.
12. Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology 1997; 49:1289-1292.
13. Rinaldi S, Willison HJ. Ganglioside antibodies and neuropathies. Curr Opin Neurol 2008; 21:540-546.
14. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:326-337.
15. Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 2006; 112:57-70.
16. Uchida J, Hamaguchi Y, Oliver JA etal. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-1669.
17. Hu CY, Rodriguez-Pinto D, Du W etal. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-3867.
18. Xiu Y, Wong CP, Bouaziz JD etal. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008; 180:2863-2875.
19. Serreze DV, Chapman HD, Niens M etal. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes 2011; 60:2914-2921.
20. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:572-577.
21. Borriello F, Sethna MP, Boyd SD etal. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 1997; 6:303-313.
22. Salek-Ardakani S, Choi YS, Rafii-El-Idrissi Benhnia M etal. B cell-specific expression of B7-2 is required for follicular Th cell function in response to vaccinia virus. J Immunol 2011; 186:5294-5303.
23. Good-Jacobson KL, Song E, Anderson S, Sharpe AH, Shlomchik MJ. CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation. J Immunol 2012; 188:4217-4225.
24. Kin NW, Sanders VM. CD86 regulates IgG1 production via a CD19-dependent mechanism. J Immunol 2007; 179:1516-1523.
25. Rozanski CH, Arens R, Carlson LM etal. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med 2011; 208:1435-1446.
26. Njau MN, Kim JH, Chappell CP etal. CD28-B7 interaction modulates short- and long-lived plasma cell function. J Immunol 2012; 189:2758-2767.
27. Kim DH, Muthyala S, Soliven B, Wiegmann K, Wollmann R, Chelmicka-Schorr E. The beta 2-adrenergic agonist terbutaline suppresses experimental allergic neuritis in Lewis rats. J Neuroimmunol 1994; 51:177-183.
28. Keren Z, Naor S, Nussbaum S etal. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. Blood 2010; 117:3104-3112.
29. Herbst R, Wang Y, Gallagher S etal. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010; 335:213-222.
30. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28:639-650.
31. Su MA, Davini D, Cheng P etal. Defective autoimmune regulator-dependent central tolerance to myelin protein zero is linked to autoimmune peripheral neuropathy. J Immunol 2012; 188:4906-4912.
32. Stoll G, Schmidt B, Jander S, Toyka KV, Hartung HP. Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system. Ann Neurol 1991; 30:147-155.
33. Tran GT, Hodgkinson SJ, Carter NM etal. Membrane attack complex of complement is not essential for immune mediated demyelination in experimental autoimmune neuritis. J Neuroimmunol 2010; 229:98-106.
34. Zhu Y, Bao L, Zhu S etal. CD4 and CD8 T cells, but not B cells, are critical to the control of murine experimental autoimmune neuritis. Exp Neurol 2002; 177:314-320.
35. Zhu W, Mix E, Jin T, Adem A, Zhu J. B cells play a cooperative role via CD40L-CD40 interaction in T cell-mediated experimental autoimmune neuritis in Lewis rats. Neurobiol Dis 2007; 25:642-648.
36. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118:3420-3430.
37. Brunn A, Utermohlen O, Sanchez-Ruiz M etal. Dual role of B cells with accelerated onset but reduced disease activity in P0(1)(0)(6)(-)(1)(2)(5)-induced experimental autoimmune neuritis of IgH (0)(/)(0) mice. Acta Neuropathol 2010; 120:667-681.
38. Weber MS, Prod'homme T, Patarroyo JC etal. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68:369-383.
39. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996; 157:4371-4378.
40. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995; 3:39-50.
41. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995; 376:352-355.
42. Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol 2003; 170:73-83.
43. DiLillo DJ, Griffiths R, Seshan SV etal. B lymphocytes differentially influence acute and chronic allograft rejection in mice. J Immunol 2011; 186:2643-2654.
44. Bouaziz JD, Yanaba K, Venturi GM etal. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007; 104:20878-20883.
45. Greeley SA, Moore DJ, Noorchashm H etal. Impaired activation of islet-reactive CD4 T cells in pancreatic lymph nodes of B cell-deficient nonobese diabetic mice. J Immunol 2001; 167:4351-4357.
46. Ziegler AI, Le Page MA, Maxwell MJ etal. The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development. Diabetologia 2013; PMID 24013782.
47. Xiang Y, Peng J, Tai N etal. The dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice. J Immunol 2012; 188:4747-4758.
48. Hamel KM, Cao Y, Ashaye S etal. B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J Immunol 2011; 187:4900-4906.
49. Bettelli E, Carrier Y, Gao W etal. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
50. Barr TA, Shen P, Brown S etal. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209:1001-1010.
51. Sun JB, Flach CF, Czerkinsky C, Holmgren J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J Immunol 2008; 181:8278-8287.
52. Ray A, Basu S, Williams CB, Salzman NH, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol 2012; 188:3188-3198.
53. Maseda D, Smith SH, DiLillo DJ etal. Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol 2012; 188:1036-1048.